FORM 4

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL					
OMB Number:	3235-0287				
stimated average burden					
ours per response	. 0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person White Barbara			Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]					5. 1	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 03/01/2017					X						
(Street) NORWOOD, MA 02062			4. If Amendment, Date Original Filed(Month/Day/Year)					_X_	6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	,	(State)	(Zip)			Table	I - N	on-Deriva	ntive Securities	Acquired	d, Disposed o	of, or Benef	icially Owne	i	
1.Title of Secur (Instr. 3)	rity		2. Transaction Date (Month/Day/Year)	2A. Deen Execution any (Month/D	Date, if	(Instr. 8)		(A) or Disposed of		f (D) Ow Tra	(D) Owned Followi Transaction(s)		1	Ownership of Form:	Beneficial
				(Month/L	ay/1ear		ode	V Aı	(A) or (D)	Price	(Instr. 3 and 4)		(Direct (D) Ownership or Indirect (Instr. 4) (I) (Instr. 4)	
Reminder: Rep	ort on a sepa	rate line for each cl	ass of securities b	enericially	owned d	irectly		Persons in this fo	who respond orm are not re tly valid OMB	quired to	o respond ι				474 (9-02)
									ed of, or Benef vertible securit		vned				
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date,	4. Transact	5. Notion Der Secon According of (Number rivative curities quired (Dispose D) str. 3, 4	of (A)	tions, con	vertible securit tercisable and Date	ies)	and Amount rlying		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(Ownersh Form of Derivativ Security: Direct (D or Indirects)	
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, any	4. Transact	5. N Der Sec Or I of ((Ins	Aumberrivative surities quired (Dispose D) str. 3, 4	of (A)	tions, con 6. Date Ex Expiration	vertible securit tercisable and I Date ay/Year)	7. Title a of Under Securities	and Amount rlying	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported	Ownersh Form of Derivativ Security: Direct (D or Indirect	p of Indirect Beneficial Ownership (Instr. 4)

Reporting Owners

December Occurs Name / Address	Relationships					
Reporting Owner Name / Address		10% Owner	Officer	Other		
White Barbara C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 100 RIVER RIDGE DRIVE NORWOOD, MA 02062			Chief Medical Officer			

Signatures

/s/ Barbara White	03/03/2017
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 1, 2018, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 1, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.